With a median price-to-sales (or "P/S") ratio of close to 5.2x in the Healthcare Services industry in Australia, you could be forgiven for feeling indifferent about Mach7 Technologies Limited's (ASX:M7T) P/S ratio, which comes in at about the same. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S. See our latest analysis for Mach7 Technologies ps-multiple-vs-industry How Mach7 Technologies Has Been Performing With revenue growth that's inferior to most other companies of late, Mach7 Technologies has been relatively sluggish. One possibility is that the P/S ratio is moderate because investors think this lacklustre revenue performance will turn around. However, if this isn't the case, investors might get caught out paying too much for the stock. If you'd like to see what analysts are forecasting going forward, you should check out our free report on Mach7 Technologies. What Are Revenue Growth Metrics Telling Us About The P/S? Mach7 Technologies' P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry. If we review the last year of revenue growth, the company posted a worthy increase of 12%. This was backed up an excellent period prior to see revenue up by 96% in total over the last three years. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth. Turning to the outlook, the next year should generate growth of 22% as estimated by the dual analysts watching the company. That's shaping up to be materially lower than the 50% growth forecast for the broader industry. With this information, we find it interesting that Mach7 Technologies is trading at a fairly similar P/S compared to the industry. Apparently many investors in the company are less bearish than analysts indicate and aren't willing to let go of their stock right now. These shareholders may be setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook. What Does Mach7 Technologies' P/S Mean For Investors? Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company. Our look at the analysts forecasts of Mach7 Technologies' revenue prospects has shown that its inferior revenue outlook isn't negatively impacting its P/S as much as we would have predicted. When we see companies with a relatively weaker revenue outlook compared to the industry, we suspect the share price is at risk of declining, sending the moderate P/S lower. A positive change is needed in order to justify the current price-to-sales ratio. The company's balance sheet is another key area for risk analysis. Our free balance sheet analysis for Mach7 Technologies with six simple checks will allow you to discover any risks that could be an issue. If companies with solid past earnings growth is up your alley, you may wish to see this freecollection of other companies with strong earnings growth and low P/E ratios. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
Mach7 Technologies Limited's (ASX:M7T) Popularity With Investors Is Under Threat From Overpricing
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...